BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%.Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P 5.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P <.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P <.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, Original Article undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51.
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INTRODUCTION
The median survival for patients with follicular lymphoma (FL) has steadily improved and now measures nearly 2 decades. 1 However, a closer examination of nearly all population-based survival curves, registrygenerated survival curves, and trial-based survival curves shows that although overall patient outcomes are improving, there has been no change in the trajectory of the curves. 2, 3 Specifically, approximately one-fifth of patients die within a few years of their diagnosis, whereas onethird of patients have long-term survival; distinguishing between these 2 groups at the initial diagnosis is not currently feasible. The continuous pattern of relapse suggests that, despite the overall improvement in survival, a cure remains elusive. Teasing out patient subsets with variable risk has been difficult, and we have no biologic markers reliably predictive of outcomes. However, there are accumulating data showing that time to event-based data can identify a subpopulation with poor survival. A pivotal National LymphoCare Study (NLCS) analysis comparing outcomes for FL patients treated with frontline rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) found highly disparate survival between patients relapsing within 24 months of their diagnosis and patients relapsing later. Specifically, the 5-year overall survival (OS) rate was only 50% with early progression of disease and 90% with late progression of disease. 4 An independent validation cohort of patients from the University of Iowa and the Mayo Clinic Molecular Epidemiology Resource data set showed even greater differences: the 5-year OS rates were 34% and 94% (hazard ratio, 20.0) for patients with early and late progression, respectively. Early treatment failure (ETF) is thus an emerging and important prognostic factor that may help to riskstratify and identify high-risk patients with an otherwise good-prognosis disease. 5 Hematopoietic stem cell transplantation (HCT) is an effective option for relapsed FL, but its role has been controversial in the rituximab era, particularly because targeted agents and less toxic therapies are in active development. Furthermore, the underlying clinical heterogeneity in FL creates considerable challenges when one is interpreting existing HCT literature. Most HCT studies are small and retrospective, include a mixture of relapsed and refractory disease states, and combine both early and late relapsing patients. [6] [7] [8] [9] [10] [11] [12] The stark survival differences realized by timeto-event analyses of FL suggest that more effective therapies are needed for patients with ETF after standard rituximab-containing chemoimmunotherapy, and it is perhaps this specific high-risk population for which HCT should be actively pursued. This approach could prevent the short-and long-term toxicities of HCT in patients who would otherwise expect to have prolonged survival while potentially offsetting the poor prognosis associated with ETF. This risk-stratified model, though appealing, currently lacks supportive data in the rituximab era, and it is further unclear whether autologous hematopoietic stem cell transplantation (auto-HCT) or allogeneic hematopoietic cell transplantation (allo-HCT) would offer the most benefit. We have, therefore, interrogated the Center for International Blood and Marrow Transplant Research (CIBMTR) database to investigate the utility of auto-HCT versus allo-HCT as the first transplantation approach for high-risk FL patients as defined by ETF.
MATERIALS AND METHODS

Data Sources
The CIBMTR is a working group of more than 500 transplantation centers worldwide that contribute detailed data on HCT to a statistical center at the Medical College of Wisconsin. Participating centers are required to report all transplants consecutively; patients are followed longitudinally, and compliance is monitored by onsite audits. Computerized checks for discrepancies, physician reviews of submitted data, and onsite audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. Protected health information used in the performance of such research is collected and maintained in CIBMTR's capacity as a public health authority under the Health Insurance Portability and Accountability Act privacy rule. The institutional review boards of the Medical College of Wisconsin and the National Marrow Donor Program approved this study.
Original Article
Patients
This analysis was aimed at comparing the transplantation outcomes of FL patients who experienced ETF after frontline rituximab-containing chemotherapies and underwent auto-HCT and FL patients with ETF who underwent either matched sibling donor (MSD) or matched unrelated donor (MUD) allo-HCT as the first transplantation approach. ETF was defined as disease relapse or progression within 2 years of the start of frontline rituximab-containing chemotherapies. Adult FL patients (age 18 years) with ETF undergoing HCT during 2002-2014 in the CIBMTR registry were eligible for this study. Patients not receiving rituximab with first-line chemotherapy or those receiving singleagent rituximab as a first-line treatment were excluded. The donor source for the allo-HCT cohort was restricted to either human leukocyte antigen-identical siblings (the MSD cohort) or 8/8 allele level-matched unrelated donors (the MUD cohort). Allo-HCT patients with a history of prior auto-HCT were excluded. Patients undergoing transformation to diffuse large B-cell lymphoma before transplantation were not eligible (n 5 16).
Definitions and Endpoints
The intensity of allo-HCT conditioning regimens was categorized as myeloablative conditioning (MAC) or nonmyeloablative conditioning/reduced-intensity conditioning (RIC) according to consensus criteria. 13 The response to therapy was determined with the International Working Group criteria. 14 The primary endpoint was OS. Death from any cause was considered an event, and surviving patients were censored at the last follow-up. Secondary outcomes included nonrelapse mortality (NRM), progression/ relapse, and progression-free survival (PFS). NRM was defined as death without evidence of lymphoma progression/relapse; relapse was considered a competing risk. Progression/relapse was defined as progressive lymphoma after HCT or lymphoma recurrence after a complete response; NRM was considered a competing risk. For PFS, a patient was considered to have suffered treatment failure at the time of progression/relapse or death from any cause. Patients alive without evidence of disease relapse/progression were censored at the last follow-up. Acute graft-versus-host disease (GVHD) and chronic GVHD were graded with established criteria.
15,16
Statistical Analysis
Patient-, disease-, and transplant-related variables were compared between the auto-HCT, MSD, and MUD cohorts with the chi-square test for categorical variables and with the Wilcoxon 2-sample test for continuous variables. Cumulative incidences of acute and chronic GVHD were calculated to accommodate for competing risks. Associations among patient-, disease-, and transplantrelated variables and outcomes of interest were evaluated with Cox proportional hazards regression. Forward stepwise selection was used to identify covariates that influenced outcomes. Covariates with a P value < .05 were considered significant. The proportional hazards assumption for Cox regression was tested by the addition of a time-dependent covariate for each risk factor and each outcome. Covariates violating the proportional hazards assumption were added as time-dependent covariates in the Cox regression model. Interactions between the main effect and significant covariates were examined. Results are expressed as the relative risk (RR). With the final Cox models, adjusted probabilities of PFS and OS and adjusted cumulative incidences of NRM and lymphoma progression/relapse were calculated as described previously. 17, 18 The variables considered in the multivariate analysis (MVA) are shown in Supporting Table 1 . All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Baseline Characteristics
Four hundred forty patients from the CIBMTR database met the criteria for the study, with the baseline characteristics listed in Table 1 . The median time from diagnosis to HCT was 24, 23, and 27 months for auto-HCT, MSD HCT, and MUD HCT, respectively. There were no significant differences in the performance status, sex distribution, race, response to first-line therapy, or median time from diagnosis to transplant between the 3 cohorts. Allo-HCT patients were younger, more heavily pretreated, and more likely to have advanced-stage disease at diagnosis. They were also more likely to have extranodal or bone marrow involvement and to be chemorefractory before transplantation. Auto-HCT patients were more likely to have grade 3 histology.
GVHD
The cumulative incidences of grade 2 to 4 acute GVHD at day 100 for the MSD and MUD cohorts were 35% and 35%, respectively (P 5 .94). The respective rates for day 100 grade 3 to 4 acute GVHD were 13% and 16% (P 5 .62). The cumulative incidences of chronic GVHD at 2 years for the MSD and MUD cohorts were not significantly different (54% vs 58%; P 5 .54)
NRM
The adjusted probability of NRM at 5 years was significantly lower in the auto-HCT group (5%) versus the (Table 3) . Other factors significantly associated with the risk of NRM included a Karnofsky performance score < 90% (RR, 2.09) and elevated lactate dehydrogenase levels (RR, 1.92; Table 3 ).
Relapse/Progression
The adjusted probability of relapse/progression at 5 years was significantly higher in the auto-HCT group (58%) versus the MSD (31%) or MUD allo-HCT group (23%; P < .0001; Table 2 and Fig. 1B) . In multivariate regression models, the main effect (auto-HCT vs MSD vs MUD) also displayed a time-varying effect on the risk of relapse/progression. During the first 7 months after transplantation (7 months was chosen as the cutoff on the basis of the maximum likelihood value in the Cox model), the risk of relapse/progression was not significantly different between the 3 HCT approaches (Table 3) ; however, after 7 months, there was a significantly lower risk of relapse/ progression in the MSD (RR, 0.38; 95% CI, 0.22-0.64; P 5 .0004) and MUD groups (RR, 0.09; 95% CI, 0.03-0.30; P < .0001) versus the auto-HCT group. Stage III/ IV at diagnosis was an independent predictor for the risk of relapse/progression (RR, 1.66; Table 3 ). Twenty-nine auto-HCT patients (12%) after relapse/progression subsequently underwent allo-HCT.
PFS
The adjusted probabilities of PFS at 5 years for the auto-HCT, MSD, and MUD cohorts were 38%, 52%, and 43%, respectively (P 5 .10; Table 2 and Fig. 1C ). In multivariate regression models, the main effect (auto-HCT vs MSD vs MUD) again displayed a time-varying effect on the risk of therapy failure. During the first 6 months after transplantation (6 months was chosen as the cutoff on the basis of the maximum likelihood value in the Cox model), there was significantly inferior PFS in the MUD cohort in comparison with the patients undergoing auto-HCT (RR, 2.60; 95% CI, 1.67-4.03; P < .0001). Beyond 6 months, both the MSD (RR, 0.67; 95% CI, 0.45-0.99; P 5 .046) and MUD groups (RR, 0.40; 95% CI, 0.23-0.71; P 5 .001) had superior PFS in comparison with the auto-HCT group (Table 3) . 
OS
The median follow-up of survivors in the auto-HCT, MSD, and MUD groups was 73, 69, and 73 months, respectively. The adjusted probability of 5-year OS was significantly higher in both the auto-HCT (70%) and MSD groups (73%) in comparison with the MUD cohort (49%; P 5 .0008; Table 2 and Fig. 1D ). In the MVA, the main effect (auto-HCT vs MSD vs MUD) again displayed a time-varying effect on the risk of mortality. During the first 24 months after transplantation (24 months was chosen as the cutoff on the basis of the maximum likelihood value in the Cox model), MUD HCT was associated with a significantly increased risk of mortality in comparison with auto-HCT (RR, 3.47; 95% CI, 2.21-5.45; P < .0001). After 24 months, MSD allo-HCT was associated with a significantly reduced risk of mortality in comparison with auto-HCT (RR, 0.29; 95% CI, 0.12-0.67; P 5 .004; Table 3 ). Other factors significantly associated with the mortality risk included extranodal involvement at HCT (RR, 1.93) and elevated lactate dehydrogenase levels (1.57; Table 3 ).
Center Effect
We evaluated the center effect with the random effects test score. No center effect was seen for NRM (P 5 .17), relapse/progression (P 5 .75), PFS (P 5 .92), or OS (P 5 .87).
Subgroup Analysis of Patients Undergoing Early HCT (1 Year From the Time of ETF)
Because the time interval between ETF and the application of HCT varied widely for each of the 3 cohorts (Table 1) , we performed a subgroup analysis of 259 patients who underwent HCT within 1 year of experiencing ETF. The baseline patient characteristics (Supporting Table 3 ) and outcomes for this subgroup (Table 4) are generally similar to those of the overall study population, with adjusted 5-year OS favoring the use of auto-HCT (73%) or MSD allo-HCT (82%) over MUD allo-HCT (47%; P 5 .0004; Table 4 ).
Alternative Definition of ETF
In a separate subgroup analysis, we redefined ETF as lymphoma relapse/progression within 1 year of the start of frontline therapies (rather than the 2-year cutoff used in the NLCS). The MVA of patients meeting this alternative definition of ETF (n 5 285), summarized in Supporting Table 4 , showed results generally in line with those of the main MVA (Table 3) , with comparable OS between the auto-HCT and MSD cohorts and inferior survival for the MUD cohort.
Conditioning Regimen
Among the allo-HCT patients, the use of MAC versus RIC had no effect on relapse, NRM, PFS, or OS in the MVA (Supporting Table 2 ).
Causes of Death and Incidence of Secondary Myelodysplastic Syndrome/Leukemia
One hundred sixty-two patients died. The most common cause of death in all 3 cohorts was relapsed disease (Table  5) , with 83% of the deaths in the auto-HCT cohort (67 of 81) and 42% in both the MSD and MUD cohorts attributable to primary disease. Notably, there were 13 cases of secondary myelodysplastic syndrome or leukemia in the auto-HCT cohort but just 1 case in the combined allo-HCT groups.
DISCUSSION
HCT is an important therapeutic option for patients with relapsed/refractory FL, but there is significant debate regarding the optimal timing and type of transplantation as well as the optimal patient population. Given the recent finding showing that early relapse adversely affects survival, 14 we sought to determine the impact of 3 transplantation strategies (auto-HCT, MSD allo-HCT, and MUD allo-HCT) in high-risk FL patients with ETF after frontline chemoimmunotherapy. Our study demonstrates that among FL patients with ETF, both auto-HCT and allo-HCT offer excellent long-term survival; the best results followed either auto-HCT or MSD HCT, with 5-year survival rates exceeding 70%. These survival figures are provocatively higher than ones predicted by the NLCS, in which only a minority of patients (8 of 110) underwent HCT. 4 These findings are consistent with a recent NLCS/ (2) 2 (6) 0 Unknown 6 (7) 2 (6) 2 (4) Abbreviations: auto-HCT, autologous hematopoietic stem cell transplantation; MSD, matched sibling donor; MUD, matched unrelated donor. a Other includes hemorrhage (n 5 1) and vascular causes (n 5 1) for the MSD group and accident/suicide (n 5 1) and vascular causes (n 5 1) for the auto-HCT group.
CIBMTR analysis in which early auto-HCT performed within 1 year of ETF improved OS in comparison with conventional chemotherapy in FL patients, 19 and they collectively suggest that transplantation should be considered in this high-risk group of patients with early relapse.
Although our results are promising, there are potential confounding variables when we are comparing outcomes with those of the NLCS or other large FL series. For example, the lower median age and performance status are generally more favorable for patients undergoing HCT, and this inherent bias could have inflated survival outcomes in our current analysis. Indeed, the median patient age in our study ranged from 52 to 56 years, depending on the specific cohort; although this age range was comparable to that for the group of patients analyzed in the NLCS (median age, 58 years), 4 it remains significantly lower than the median age of the typical FL patient. 2 However, patients undergoing HCT are also more likely to harbor important unfavorable features, including a high frequency of chemorefractory or heavily pretreated disease. In our analysis, 32% of the patients had chemorefractory disease, and more than 50% had received at least 3 prior therapy lines. Furthermore, we included patients with grade 3 FL to be consistent with the NLCS. Although many series evaluating non-HCT modalities have shown inferior survival for grade 3 disease, 20 grade did not emerge as predictive of relapse or survival in our analysis.
A major clinical challenge for patients with relapsed FL undergoing HCT is the selection between autologous and allogeneic approaches. Similarly to other registry analyses, patients undergoing allo-HCT had higher risk disease with more lines of prior therapy, had more advanced-stage disease, and more frequently had chemorefractoriness at the time of transplantation. The observation of significantly lower 5-year relapse rates in the 2 allo-HCT cohorts despite these adverse features is noteworthy and demonstrates that potent graft-versuslymphoma effects are operational even in the highest risk FL patients. When one is deciding between auto-HCT and allo-HCT for ETF FL, auto-HCT may be a preferred option for chemosensitive ETF patients with fewer than 2 or 3 prior therapies and no marrow involvement (especially because, after auto-HCT, failures can be salvaged with subsequent allo-HCT). MSD HCT could be the first transplantation approach for heavily pretreated patients or those with refractory disease, marrow involvement, or mobilization failures. MUD HCT might be best deferred until relapse/progression after auto-HCT. Although a single-institution study has suggested a benefit of allo-HCT over auto-HCT in patients with FL relapsing within 1 year of prior therapy, 21 our subgroup analysis using this alternative definition of ETF did not confirm any benefit of allo-HCT over auto-HCT in this setting (Supporting Table 4 ).
A somewhat unexpected outcome of our study was the significantly higher NRM in the MUD cohort versus the MSD cohort, which resulted in inferior 5-year survival. This finding is in contrast to other studies showing similar OS with MSD and MUD allo-HCT for FL. 9, 22 The distribution of patient characteristics, preparative regimens used (Table 1) , and causes of death in the MUD and MSD cohorts appeared similar ( Table 5 ). The more frequent use of anti-thymocyte globulin or alemtuzumab in the MUD cohort versus the MSD cohort (Table 1) could be a possible explanation. 23 In addition, the significantly inferior postrelapse survival of the MUD cohort versus the MSD group (OS 4 years after relapse, 33% vs 64%; P 5 .02; Supporting Table 5 ) may underlie the inferior outcomes of the MUD cohort. There was also no apparent survival advantage from a MAC regimen, which is consistent with other reports, and this also supports the selection of RIC as another method for reducing NRM. Novel nontransplant therapies continue to challenge the overall role and optimal timing of HCT. Immunomodulatory agents such as lenalidomide and phosphatidylinositol 3-kinase (PI3K) inhibitors (eg, idelalisib and copanlisib) have significant activity in relapsed FL (as reviewed by Kahl and Yang 25 ). Because ETF patients may have intrinsic resistance to chemotherapy, perhaps these novel agents could be more effective than conventional chemotherapy or high-dose chemotherapy. An upcoming US Intergroup study is evaluating lenalidomide, the PI3Kd inhibitor TGR-1202, and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, all in combination with obinutuzumab, specifically in FL patients with ETF, and it will be highly informative regarding the role of targeted and biologic therapies in FL patients with ETF. Thus, we must critically examine the outcomes of FL with modern non-HCT approaches. Significant progress has been made, but a cure with novel agents remains elusive, the duration of disease control is modest at best (eg, the median PFS is approximately 11 months with idelalisib for FL patients with ETF and approximately 12 months with lenalidomide/rituximab 26, 27 ), and therapy-related morbidity in certain studies rivals numbers seen with auto-HCT. 28 Moreover, the cost of these often continuous therapies with newer agents should be factored into medical decision making. T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia and B-cell lymphomas. 29 No data are currently available about CAR-19 specifically in ETF FL, but this warrants further investigation.
Although observational registry studies have inherent limitations, prospective, randomized studies comparing various HCT approaches to FL with ETF are unlikely to be performed. In the absence of such data, our analysis provides vital information for clinical decision making for these high-risk FL patients. In summary, our data support HCT as an appropriate and effective option for transplanteligible FL patients with ETF because of the noted longterm survival of 70% of patients undergoing either auto-HCT or MSD allo-HCT. Although MUD allo-HCT has excellent disease control, high NRM was associated with inferior OS. MSD allo-HCT may be preferred over auto-HCT in chemorefractory patients, although there is a balance between higher initial toxicity and longer term PFS. Until better risk-stratification tools are available for FL, auto-HCT and MSD allo-HCT should be considered as effective treatment options with excellent long-term survival for high-risk patients as defined by ETF.
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